Towards clinical TCR gene therapy: tumor models and receptors

- Trudy Straetemans

To date, adoptive T cell therapy seems one of the most promising therapies for patients with metastatic melanoma. Adoptive transfer of autologous Tumor Infiltrating T cells (TILs), cultured and expanded ex vivo, yields impressive objective response rates of 50% in noncontrolled trials in patients with metastatic melanoma. T cell receptor gene therapy (TCR gene therapy) lifts adoptive T cell therapy to another level in an effort to make T cell treatment more universal with respect to tumor target antigens and suitable for the treatment of tumors of different histological origins. TCR gene therapy is based on the transfer of genes encoding for a tumor-specific TCR into autologous T cells, rapid expansion ex vivo and the re-infusion of T cells into the patient. In contrast to TIL therapy, TCR gene therapy is not dependent on the presence of TILs and the isolation of tumor material from the patient.

@ Erasmus MC / Erasmus University Rotterdam

#proefschrift #dissertatie #thesis #layout #epub #design @ogc.nl

http://bit.ly/2lp6StD